Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD | O00767 | 1/20 | 0.35 |
| ▸ | CLPP | Q16740 | 3/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.33 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.32 |
| ▸ | DRD4 | P21917 | 1/20 | 0.32 |
| ▸ | UBE2M | P61081 | 2/20 | 0.32 |
| ▸ | DCUN1D1 | Q96GG9 | 2/20 | 0.32 |
| ▸ | GRM2 | Q14416 | 3/20 | 0.32 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17537037 | 0.89 | SCD (0.34) | SCDCLPPKCNH2LMNASMN1; SMN2 | |
| SCHEMBL16185202 | 0.88 | SCD (0.39) | SCDCLPPKCNH2LMNASMN1; SMN2 | |
| SCHEMBL16185235 | 0.85 | KCNH2 (0.39) | SCDCLPPKCNH2LMNASMN1; SMN2 | |
| Trifluoroacetic Acid SCHEMBL17537010 | 0.84 | SCD (0.36) | SCDCLPPKCNH2LMNASMN1; SMN2 | |
| SCHEMBL16185240 | 0.84 | SCD (0.37) | SCDCLPPKCNH2LMNASMN1; SMN2 | |
| SCHEMBL16185297 | 0.83 | SCD (0.39) | SCDCLPPKCNH2LMNASMN1; SMN2 | |
| SCHEMBL16180509 | 0.83 | SCD (0.39) | SCDCLPPKCNH2LMNASMN1; SMN2 | |
| SCHEMBL16185301 | 0.81 | SCD (0.39) | SCDCLPPKCNH2LMNASMN1; SMN2 | |
| SCHEMBL16185210 | 0.81 | KCNH2 (0.36) | SCDCLPPKCNH2LMNASMN1; SMN2 | |
| SCHEMBL17537049 | 0.81 | KCNH2 (0.36) | SCDCLPPKCNH2LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9493479-B2 | Substituted pyrido[1,2-a]pyrazines as HIV integrase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-11-15 | — | — | US | disclosed |
| US-20160060272-A1 | 4-PYRIDONE DERIVATIVE COMPOUNDS AND USES THEREOF AS HIV INTEGRASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160060272-A1 | 4-PYRIDONE DERIVATIVE COMPOUNDS AND USES THEREOF AS HIV INTEGRASE INHIBITORS | PNPO, TYMP, PDXK | SCD 2858/4885CLPP 2603/4885KCNH2 2585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.